Nazione: Stati Uniti
Lingua: inglese
Fonte: NLM (National Library of Medicine)
ACITRETIN (UNII: LCH760E9T7) (ACITRETIN - UNII:LCH760E9T7)
Amneal Pharmaceuticals of New York LLC
ACITRETIN
ACITRETIN 10 mg
ORAL
PRESCRIPTION DRUG
Acitretin capsules are indicated for the treatment of severe psoriasis in adults. Because of significant adverse effects associated with its use, acitretin capsules should be prescribed only by those knowledgeable in the systemic use of retinoids. In females of reproductive potential, acitretin capsules should be reserved for non-pregnant patients who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments (see boxed CONTRAINDICATIONS AND WARNINGS — acitretin capsules can cause severe birth defects). Most patients experience relapse of psoriasis after discontinuing therapy. Subsequent courses, when clinically indicated, have produced efficacy results similar to the initial course of therapy. Pregnancy Category X ( See boxed CONTRAINDICATIONS AND WARNINGS) Acitretin is contraindicated in patients with severely impaired liver or kidney function and in patients with chronic abnormally elevated blood lipid values (see boxed WARNINGS: Hepatotoxicity, WARNINGS: Lipids and Possible Cardiovascular Effects , and PRECAUTIONS ). An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate. Consequently, the combination of methotrexate with acitretin is also contraindicated (see PRECAUTIONS: Drug Interactions ). Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated (see WARNINGS: Pseudotumor Cerebri ). Acitretin is contraindicated in cases of hypersensitivity (e.g., angioedema, urticaria) to the preparation (acitretin or excipients) or to other retinoids.
Acitretin Capsules USP, 10 mg are supplied as white to off-white body and a brown cap, imprinted in black “IX” on the capsule cap and “667” on the capsule body. They are available as follows: Bottles of 30: NDC 0115-1750-08 Acitretin Capsules USP, 17.5 mg are supplied as yellow to light yellow body and cap, imprinted in black “IX” on the capsule cap and “668” on the capsule body. They are available as follows: Bottles of 30: NDC 0115-1751-08 Acitretin Capsules USP, 22.5 mg are supplied as brown body and cap, imprinted in black with “IX” on the capsule cap and “698” on the capsule body. They are available as follows: Bottles of 30: NDC 0115-1752-08 Acitretin Capsules USP, 25 mg are supplied as yellow to light yellow body and a brown cap, imprinted in black “IX” on the capsule cap and “669” on the capsule body. They are available as follows: Bottles of 30: NDC 0115-1753-08 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light. Avoid exposure to high temperatures and humidity after the bottle is opened.
Abbreviated New Drug Application
Amneal Pharmaceuticals of New York LLC ---------- MEDICATION GUIDE ACITRETIN (A”SIT RE’ TIN) CAPSULES, USP Read this Medication Guide carefully before you start taking acitretin, and read it each time you get more acitretin. There may be new information. The first information in this Medication Guide is about birth defects and how to avoid pregnancy. After this section there is important safety information about possible effects for any patient taking acitretin. All patients should read this entire Medication Guide carefully. This information does not take the place of talking with your prescriber about your medical condition or treatment. What is the most important information I should know about acitretin? Acitretin can cause serious side effects, including: • Severe birth defects. If you are a female who can get pregnant, you should use acitretin only if you are not pregnant now, can avoid becoming pregnant for at least 3 years, and other medicines do not work for your severe psoriasis or you cannot use other psoriasis medicines. Information about effects on unborn babies and about how to avoid pregnancy is found in the next section: “What are the important warnings and instructions for females taking acitretin?” • Liver problems, including abnormal liver function tests and inflammation of your liver (hepatitis). Your prescriber should do blood tests to check how your liver is working before you start taking and during treatment with acitretin. Stop taking acitretin and call your prescriber right away if you have any of the following signs or symptoms of a serious liver problem: • yellowing of your skin or the whites of your eyes • nausea and vomiting • loss of appetite • dark urine What are the important warnings and instructions for females taking acitretin? • Before you receive your first prescription for acitretin, you should have discussed and signed a Patient Agreement/Informed Consent for Female Patients form with your prescriber. This is to help make sure you understand the risk o Leggi il documento completo
ACITRETIN- ACITRETIN CAPSULE AMNEAL PHARMACEUTICALS OF NEW YORK LLC ---------- ACITRETIN CAPSULES, USP (10 MG, 17.5 MG, 22.5 MG AND 25 MG) RX ONLY CONTRAINDICATIONS AND WARNINGS: PREGNANCY ACITRETIN MUST NOT BE USED BY FEMALES WHO ARE PREGNANT, OR WHO INTEND TO BECOME PREGNANT DURING THERAPY OR AT ANY TIME FOR AT LEAST 3 YEARS FOLLOWING DISCONTINUATION OF THERAPY. ACITRETIN ALSO MUST NOT BE USED BY FEMALES WHO MAY NOT USE RELIABLE CONTRACEPTION WHILE UNDERGOING TREATMENT AND FOR AT LEAST 3 YEARS FOLLOWING DISCONTINUATION OF TREATMENT. ACITRETIN IS A METABOLITE OF ETRETINATE (TEGISON ), AND MAJOR HUMAN FETAL ABNORMALITIES HAVE BEEN REPORTED WITH THE ADMINISTRATION OF ACITRETIN AND ETRETINATE. POTENTIALLY, ANY FETUS EXPOSED CAN BE AFFECTED. CLINICAL EVIDENCE HAS SHOWN THAT CONCURRENT INGESTION OF ACITRETIN AND ETHANOL HAS BEEN ASSOCIATED WITH THE FORMATION OF ETRETINATE, WHICH HAS A SIGNIFICANTLY LONGER ELIMINATION HALF-LIFE THAN ACITRETIN. BECAUSE THE LONGER ELIMINATION HALF-LIFE OF ETRETINATE WOULD INCREASE THE DURATION OF TERATOGENIC POTENTIAL FOR FEMALE PATIENTS, ETHANOL MUST NOT BE INGESTED BY FEMALE PATIENTS OF CHILDBEARING POTENTIAL EITHER DURING TREATMENT WITH ACITRETIN OR FOR 2 MONTHS AFTER CESSATION OF THERAPY. THIS ALLOWS FOR ELIMINATION OF ACITRETIN, THUS REMOVING THE SUBSTRATE FOR TRANSESTERIFICATION TO ETRETINATE. THE MECHANISM OF THE METABOLIC PROCESS FOR CONVERSION OF ACITRETIN TO ETRETINATE HAS NOT BEEN FULLY DEFINED. IT IS NOT KNOWN WHETHER SUBSTANCES OTHER THAN ETHANOL ARE ASSOCIATED WITH TRANSESTERIFICATION. ACITRETIN HAS BEEN SHOWN TO BE EMBRYOTOXIC AND/OR TERATOGENIC IN RABBITS, MICE, AND RATS AT ORAL DOSES OF 0.6, 3, AND 15 MG PER KG, RESPECTIVELY. THESE DOSES ARE APPROXIMATELY 0.2, 0.3, AND 3 TIMES THE MAXIMUM RECOMMENDED THERAPEUTIC DOSE, RESPECTIVELY, BASED ON A MG- PER-M COMPARISON. MAJOR HUMAN FETAL ABNORMALITIES ASSOCIATED WITH ACITRETIN AND/OR ETRETINATE ADMINISTRATION HAVE BEEN REPORTED INCLUDING MENINGOMYELOCELE; MENINGOENCEPHALOCELE; MULTIPLE SYNOSTOSES; FACIAL DYSMORPHIA; SYNDACTYL Leggi il documento completo